Ballentine Partners’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
Ballentine Partners's DGX Position: Q3 2026 in Review
Ballentine Partners increased its Quest Diagnostics (DGX) stake by 5.8% in Q3 2026, buying an estimated $41.1K and bringing the position to 3,236 shares worth $754K. The position accounts for 0.01% of the portfolio, ranked #462.
Ballentine Partners first reported a position in DGX in Q2 2017 and has held it in 9 quarters since. 1,142 funds tracked by Wall St. Rank hold DGX as of Q3 2026.
- Ballentine Partners held 3,236 shares of Quest Diagnostics worth $754K as of Q3 2026.
- Ballentine Partners bought 178 Quest Diagnostics shares in Q3 2026, an estimated $41.1K.
- Quest Diagnostics made up 0.01% of Ballentine Partners's portfolio in Q3 2026, its #462 holding.
- Ballentine Partners first reported a position in Quest Diagnostics in Q2 2017 and has held it in 9 quarters since.
- 1,142 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2026.
Based on Ballentine Partners's 13F filing for Q3 2026, filed 13 Nov 2026.